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STUDY PROTOCOL

Open Access

Design of a prostate cancer patient navigation
intervention for a Veterans Affairs hospital
Narissa J Nonzee1,2, June M McKoy1,3,4, Alfred W Rademaker1,4, Peter Byer1, Thanh Ha Luu5, Dachao Liu1,4,
Elizabeth A Richey6, Athena T Samaras5, Genna Panucci7, XinQi Dong8 and Melissa A Simon1,4,5*

Abstract
Background: Patient navigation programs have been launched nationwide in an attempt to reduce racial/ethnic
and socio-demographic disparities in cancer care, but few have evaluated outcomes in the prostate cancer setting.
The National Cancer Institute-funded Chicago Patient Navigation Research Program (C-PNRP) aims to implement
and evaluate the efficacy of a patient navigation intervention for predominantly low-income minority patients with
an abnormal prostate cancer screening test at a Veterans Affairs (VA) hospital in Chicago.
Methods/Design: From 2006 through 2010, C-PNRP implemented a quasi-experimental intervention whereby
trained social worker and lay health navigators worked with veterans with an abnormal prostate screen to
proactively identify and resolve personal and systems barriers to care. Men were enrolled at a VA urology clinic and
were selected to receive navigated versus usual care based on clinic day. Patient navigators performed activities to
facilitate timely follow-up such as appointment reminders, transportation coordination, cancer education,
scheduling assistance, and social support as needed. Primary outcome measures included time (days) from
abnormal screening to diagnosis and time from diagnosis to treatment initiation. Secondary outcomes included
psychosocial and demographic predictors of non-compliance and patient satisfaction. Dates of screening, follow-up
visits, and treatment were obtained through chart audit, and questionnaires were administered at baseline, after
diagnosis, and after treatment initiation. At the VA, 546 patients were enrolled in the study (245 in the navigated
arm, 245 in the records-based control arm, and 56 in a subsample of surveyed control subjects).
Discussion: Given increasing concerns about balancing better health outcomes with lower costs, careful
examination of interventions aimed at reducing healthcare disparities attain critical importance. While analysis of
the C-PNRP data is underway, the design of this patient navigation intervention will inform other patient navigation
programs addressing strategies to improve prostate cancer outcomes among vulnerable populations.
Keywords: Patient navigation, Prostate cancer, Cancer health disparities, Veterans

Background
Prostate cancer is the second leading cause of cancerrelated deaths and the most common non-skin cancer
malignancy among men in the United States, accounting
for nearly one-third of all newly diagnosed cancers. An
estimated 240,000 men were newly diagnosed with prostate cancer in 2011 [1]. Despite attempts to minimize
gaps in health care, African American men are
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disproportionately burdened by prostate cancer compared to all other racial and ethnic groups in the U.S.
The mortality rate for prostate cancer is an estimated
2.4 times greater among African American men than
their white counterparts [2].
In 1995, an initiative that demonstrated efficacy in reducing health disparities among low-income minority
women with an abnormal breast screening test in
Harlem, New York, resulted in the launching of patient
navigation programs nationwide [3,4]. Patient navigators
are defined as advocates who interface with patients to
identify and remove barriers to completing follow-up for
cancer-related care [5]. In 2005, the National Cancer Institute (NCI) funded eight geographically and culturally
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unique sites for the Patient Navigation Research Program (PNRP); a ninth site was funded by the American
Cancer Society (ACS). The PNRP aimed to improve
follow-up care for undeserved individuals with abnormal
screening tests for the breast, cervix, prostate, or colon/
rectum [6].
The PNRP chose to navigate prostate cancer, a disease
requiring complex decision-making and unequivocally
diagnosed with the prostate-specific antigen (PSA) test;
then, the PSA was standardized in clinical guidelines
and widely utilized [7,8]. Over the past five years, increasing attention has been directed at the impact of
PSA screening tests on prostate cancer mortality rates.
A recent 13-year update to the cooperative Prostate,
Lung, Colorectal, and Ovarian (PLCO) Cancer Screening
Trial reported no significant difference in prostate cancer death rate between the screened and control groups
[9]. Conversely, the 11-year update to the European Randomized Study of Screening for Prostate Cancer
(ERSPC) reconfirmed that PSA-based screening reduced
the rate of death from prostate cancer [10]. The continuation of conflicting results, in addition to the U.S. Preventive Services Task Force recommendation against
PSA-based screening in asymptomatic men [11], underscore the need for a careful examination of patient navigation methodologies and consideration of populations
likely to benefit from targeted interventions.
Evidence regarding whether an equal access health
care system attenuates cancer health disparities also
remains unsettled. Some studies suggest that the association between race or socioeconomic status and prostate
cancer outcomes may diminish in equal access health
care settings such as the Veterans Affairs (VA) system
[12-14], while others demonstrate persistence of these
disparities irrespective of reduced financial barriers to
care [15-18]. Thus, the Chicago Patient Navigation Research Program (C-PNRP) was implemented at a VA
hospital for men with an abnormal prostate screening
test result. Patient navigators, working within the VA
system, assisted veterans in proactively identifying barriers to keeping scheduled appointments and adhering
to prostate cancer treatment modalities. Our study
recruited 546 subjects with an abnormal prostate cancer
screening test; data analyses are currently underway. We
anticipate that our program design, planned outcome
evaluations, and lessons learned presented in this paper
will inform the development of future patient navigation
interventions for underserved men with abnormal prostate cancer screening tests.

Methods/Design
Conceptual framework

We incorporated aspects of two main models to guide our
navigation framework. Based on Bastani et al.’s model for
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intervention research, dissemination, and implementation [19] describing four levels of interventions (patient-,
provider-, practice-, and policy-targeted) to improve
follow-up after abnormal screening tests, the project was
designed to include a multi-tiered care management team
comprising a nurse practitioner, social worker, and lay
health navigator and later modified to include only a social
worker and lay health navigator who worked closely with
clinic-based nurses. The team was formulated to address
barriers present at each level and tailored navigation to
the identified needs of each patient. Our navigation model
was also rooted in a modified Chronic Care Model [20],
representing a system rather than an individual and existing within a network framework whereby navigators
assisted veterans in mitigating multifaceted barriers to
obtaining follow-up care at the individual, health care system, and community levels. Our navigators were taskoriented (identifying and mitigating patient and systems
barriers) and facilitative (supporting the actions of the
patients).
Study outcomes

The C-PNRP was administered through Northwestern
University, and the prostate arm was fielded through a
tertiary care VA hospital. The national PNRP aims
included time to diagnostic resolution, time to treatment
initiation, patient satisfaction, and cost-effectiveness [6].
Specific aims in Chicago included (1) increasing the proportion of patients with diagnostic evaluations among
navigated men compared to controls receiving usual
care; (2) for patients who receive follow-up diagnostic
evaluations, improving the time between abnormal
screening and diagnostic resolution compared to controls; (3) for patients with cancer, improving the time between diagnostic resolution and treatment initiation
among navigated men compared to controls and; (4)
identifying patient characteristics associated with diagnostic evaluation delay and patient satisfaction. Diagnostic resolution is defined as the date of the diagnostic test
(either a biopsy or follow-up PSA test) that resolved the
screening test into a positive cancer diagnosis or negative cancer diagnosis (either a resolution based on pathology or a PSA level/velocity determined to be within
normal range). Treatment initiation is defined as the
first date of treatment received for either single or combination therapy.
Study site selection

Our study was implemented in an urban VA hospital,
which provided guaranteed financial access to follow-up
care after a positive prostate cancer screening test. The
VA and its four community based outpatient clinics provide care for approximately 58,000 veterans in Chicago,
Cook County (the county in which Chicago resides), and
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northwest Indiana. Nearly half of veterans in Cook
County are 65 years of age or older [21], and a large proportion is African American. Previous work by our
collaborators at the Chicago VA revealed that literacy
may impact early-stage prostate cancer diagnosis among
low-income men [22]. Moreover, among veterans with
prostate cancer, older age and lower literacy skills were
predictors of high PSA levels [23]. Thus, overcoming
potential barriers to timely follow-up such as age, cultural beliefs, and literacy played an important role at
this site.
Needs assessment

The first year of the program was dedicated to better
understanding patient and systems barriers to timely
prostate cancer care at the VA. Semi-structured questionnaires were administered to two groups: key informants (medical and administrative staff ) and patients
who had not followed up on an abnormal screening test
within 6 months. The key informant questionnaire focused
on established processes for screening, diagnosis, treatment, and missed appointments. The patient questionnaire focused on screening behavior, rationales for
delaying care, social support, and facilitators to care. Together, the responses helped to inform the development of
the study protocol and to determine the times at which
patient navigation could intersect the flow of usual care.
Community advisory board

To inform the development, implementation, and sustainability of the navigation program, a community advisory board (CAB) was assembled. The VA advisory
board met on multiple occasions throughout the project
period and included leaders in their respective fields: the
physician principal investigator of the project, a physician co-investigator, a former VA Chief of Staff, the director of the ACS-Illinois patient navigation services,
former veteran cancer survivors, the Chief Executive
Officer of a community cancer non-profit organization,
and the assistant to a Congressman whose district comprises a large African American population. The members’ range of expertise in personal cancer management,
clinical treatment of prostate cancer, health care systems,
community outreach, and health policy contributed
valuable input and feedback relative to the development
of a culturally-sensitive program geared at vulnerable
populations. In summary, CAB members gave voice to
the underserved segments of the Chicago community.
Study design

The study used a quasi-experimental design. Eligible
patients included men 18 years of age or older with an abnormal prostate cancer screening test (PSA ≥ 4.0 ng/mL,
PSA < 4.0 ng/mL with abnormal velocity, or abnormal
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digital rectal exam) and who, following consultation with a
specialist, were recommended for biopsy. Exclusion criteria
included cognitive impairment as defined by documentation of dementia in medical charts, institutionalization,
previous navigation for an abnormal cancer screen or diagnosis, and a prior history of cancer except non-melanoma
skin cancer that was treated within the past five years. Eligibility was reviewed via the VA’s electronic medical record
system. Patients were selected to receive navigation if they
met inclusion criteria and presented to the urology clinic
for follow-up on a clinic day designated for the navigation
intervention (n = 245). Patients who presented for followup on a clinic day designated for non-intervention were
selected as controls (n = 245). The urology clinic was
staffed with rotating resident physicians and a permanent
team of attending physicians and nurses across navigation
and non-navigation days.
Patients were approached for participation in the study
following a referral from a nurse practitioner or urologist. As illustrated in Figure 1, patient navigators facilitated assistance through diagnostic resolution for
patients without prostate cancer, completion of primary
therapy for patients with prostate cancer, or end of
study. The control group received usual care and comprised a concurrent records-based sample. A subsample
of control subjects who completed a diagnostic evaluation (n = 56) were prospectively enrolled for the questionnaire portion of the study only. Written informed
consent and authorization were obtained from the navigated and prospective control patients, and a waiver
of authorization was granted for the records-based
control arm. All study procedures were approved by the
Northwestern University Institutional Review Board (IRB),
Jesse Brown VA Medical Center Research & Development
Committee, and the Collaborative IRB of the University of
Illinois at Chicago.
Data collection and survey administration

Clinical data elements such as visit dates, test results,
and baseline comorbid conditions [24] were abstracted
from the VA’s computerized electronic medical record
system (CPRS) by trained research personnel in accordance with the data dictionary developed by the PNRP
[6]. CPRS allowed researchers to access primary care
records from VA community-based outpatient clinics as
well as treatment records from other VA tertiary care
centers. Data were initially recorded on case report
forms and subsequently entered into electronic databases. As part of quality control and assurance measures, a subset of chart audits were independently
performed by teams of research personnel (N.N., P.B.,
T.H., and E.R.) to ensure uniformity in data collection.
Any missing data or discrepancies were documented and
adjudicated by clinical investigators (M.S. and J.M.). The

Nonzee et al. BMC Health Services Research 2012, 12:340
http://www.biomedcentral.com/1472-6963/12/340

Page 4 of 9

Abnormal Screen
[PSA or DRE]
Time 0: Baseline
Questionnaire
Diagnostic Test
[biopsy, follow-up PSA]

No Resolution

Exit

Resolution

Time 1: (+) Diagnosis
Questionnaire
[within 3 months]

Cancer

Treatment
Initation

Time 2: Treatment
Questionnaire
[3 months after initiation]

prostatectomy, radiation,
hormones, cryotherapy

No cancer

Time 1: (-) Diagnosis
Questionnaire
[within 3 months]

Exit

watchful
waiting

Exit

Treatment
Completion

Exit

Figure 1 Study flow chart. Men were enrolled following referral for either an abnormal prostate specific antigen or digital rectal screening test
and navigated through diagnostic resolution for patients without prostate cancer, treatment completion for those with prostate cancer, or end of
study. Questionnaires were administered at baseline, within 3 months of diagnosis, and 3 months after treatment initiation to navigated subjects
and a subsample of controls.

program and data manager resolved all responses in the
final dataset.
Psychosocial assessments were administered to participants in person or by telephone at baseline, following
diagnosis, and if applicable, after treatment initiation
(Figure 1). Table 1 illustrates questionnaire measures
and specific administration time points. For navigated
participants, data on demographics, health literacy [25],
perceived stress [26], social support [27], locus of control
[28], health care system distrust [29], self-efficacy [30],
impact of events [31], patient satisfaction with care [32],
and patient satisfaction with navigation [33] scales were
collected. For the subsample of prospective control participants, trained research assistants collected data on
demographics, self-efficacy, impact of events, and satisfaction with care at diagnosis and treatment to contribute to the multi-center PNRP analysis.
In addition to clinical and psychosocial data, patient
navigators recorded each activity they performed for or
on behalf of the patient on tracking logs. Data elements
included encounter date, encounter type (telephone, inperson, interaction with third party), length of encounter, barrier type, actions taken to resolve barrier, and
length of time to complete each action.

Patient navigators
Recruitment and characteristics of navigators

The navigation team consisted of two full-time navigators: a social worker with an advanced degree and a
college-educated lay health worker. A nurse practitioner
was also included in the original navigation framework;
however, because the nurse practitioner’s navigation role
duplicated clinical services present within the VA, such
as cancer treatment education, we modified the team to
include a lead social worker and lay patient navigator who
regularly collaborated with clinical providers at the VA.
The navigator team consisted of white and African
American navigators, mirroring the cultural composition
of the VA. Additionally, because the study population was
exclusively male veterans with gender-specific care needs,
the project actively sought male patient navigators.
Training of patient navigators

Patient navigators were trained on a national, state, and
local level. Navigators attended annual training conferences sponsored by the NCI and the ACS, which focused
on exposure to various patient navigator types, development of resource tools for patients, and enhancement of
communication and collaboration skills [34]. At the state
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Table 1 Psychosocial questionnaire measures and administration times
Baseline/outcome measure

Questionnaire

Survey administration times
Baseline

Time 1

Time 2

(after referral for (within 3 months (within 3 months
(3 months
abnormal screen)
of negative
of positive
after treatment
diagnosis)
diagnosis)
initiation)
Health literacy

Rapid Estimate of Adult Literacy
in Medicine [25]

X

Comorbid conditions that
may alter risk of mortality

Charlson Comorbidity Index [24]

X

Anxiety and stress

Perceived Stress Scale [26]

X

Perceived functional support

Medical Outcomes Study-Social
Support Survey [27]

X

Predisposition for fatalistic
attitudes directed at health

Wallston Multi-Dimensional
Locus of Control [28]

X

Distrust towards health
care system

Health Care System Distrust [29]

X

Patient engagement in own
health care

*Communication and Attitudinal
Self-Efficacy - General [30]

Patient engagement in
own cancer care

*Communication and Attitudinal
Self-Efficacy - Cancer [30]

Subjective distress related
to a specific event

*Impact of Events [31]

X

X

X

Satisfaction with
cancer-related care

*Patient Satisfaction with Care [32]

X

X

X

Satisfaction with patient
navigation services

Patient Satisfaction with Navigator [33]

X

X

X

X
X

X

X
X

*Administered to a subsample of prospective control participants for national PNRP analysis.

level, the lead social worker navigator participated in
monthly patient navigation-focused training sessions
facilitated through the ACS-Illinois. Locally, study investigators trained all navigators on the consent process, research surveys, and cultural and communication barriers.
Further, discussion of challenging cases, effective navigation strategies, and clinical terminology were incorporated
into weekly meetings. Navigators also completed human
subject research training and participated in relevant VA
human subjects, patient education, and electronic medical
record training sessions at the clinic site as needed. Navigators were evaluated at the clinic site on a quarterly basis
and supervised by the project manager and two ACS
representatives specializing in patient navigation services.
Patient navigator intervention
Navigation activities

The navigation team was formally credentialed by the
VA and directly interfaced with patients both in person
and by telephone. On the day of enrollment, navigators
assessed for barriers in person in the urology clinic. To
address the barriers, navigators completed activities,
such as interacting with providers and the healthcare
system on patients’ behalf, addressing psychosocial
issues, performing appointment reminder calls, linking
patients with resources, coordinating transportation, and

facilitating patient education and responses to clinical
questions. Moreover, since navigators were based in the
VA with access to updated electronic medical records,
they were able to monitor patients’ progress in real-time
and meet with them face-to face at clinic visits, particularly treatment appointments in order to provide social
support. Our navigators worked with medical and nonmedical clinic staff to resolve emerging issues, and if unable to do so with their assistance, connected patients
with VA and community organizations. Though each patient navigator had his individual caseload, the social
worker navigator provided consultation to the lay navigator on issues that required specialized expertise.
Navigation intensity (total time spent with or on behalf of
a patient) varied on a case-by-case basis and was determined
predominantly by the patient’s existing social support
network, barriers identified, and selection of treatments
that required repeat visits, such as radiation therapy. At
minimum, each patient received an initial assessment of
barriers and standardized appointment reminders. On
average, navigators spent twice as much time with patients
who had cancer compared with those without cancer.
Appointment reminder system

Navigators completed systematic appointment reminders
to prevent missed clinic visits and aided patients in
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canceling or rescheduling appointments when necessary
to avoid delays in diagnostic resolution. Navigators also
made initial reminder telephone calls to each patient
one month prior to his scheduled prostate needle biopsy
and utilized these calls to review procedure-related preparatory instructions, since lack of adherence to these
instructions often resulted in a rescheduled appointment. For patients who could not be directly reached at
their valid primary telephone number, navigators left a
voicemail appointment reminder upon repeat contact. A
second appointment reminder was made ten days prior to
the scheduled biopsy to ensure that patients remained adherent to preparatory instructions. If the patient, through
previous interaction with their navigator, expressed difficulty remembering appointment times, the navigator performed a third reminder call prior to the biopsy date.
Patients diagnosed with prostate cancer received additional reminder calls throughout treatment as needed.
Data analysis plan

National outcome measures will be evaluated by the Patient Navigation Research Program [6,35,36]. Table 2
presents the patient characteristics of the study sample
for our local analysis (n = 490). The majority was greater
than 65 years of age (53%), African American (68%), and
referred to our program based on an abnormal PSA test
(84%); over one-third were diagnosed with prostate cancer. Plans to analyze our local outcomes are described
below.
Power calculation

Based on our group’s previous prostate cancer research
at the VA, we estimated that the mean time from abnormal screen to diagnostic resolution (Time 1) in the control group would be 103 days and the mean time from
cancer diagnosis to treatment initiation (Time 2) in cancer patients would be 128 days. The initial power calculation indicated that for Time 1, 300 patients per group
would have 80% power to detect a mean Time 1 of
86 days in the navigated group, and that 120 cancer
patients per group would have 80% power to detect a
mean Time 2 of 90 days in the navigated group. Since
only 245 rather than 300 patients were enrolled per
group for Time 1, the actual effect size for Time 1 that
was detectable with 80% power was 103 days versus
84 days. Since only 85 rather than 120 patients were enrolled per group for Time 2, the actual effect size for
Time 2 that was detectable with 80% power was 128 days
versus 82 days. Two-tailed tests and a Type I error rate
of 5% were assumed.
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Table 2 Patient characteristics, abnormal screen group
(n = 490)
All subjects (n = 490)
N (%)
Age
< 65 years

261 (53%)

> = 65 years

229 (47%)

Mean

65.1

Median

63.5

Range

42-92

Race/ethnicity
African American

332 (68%)

White

105 (21%)

Other

27 (6%)

Not reported

26 (5%)

Screening eligibility
PSA test (> = 4.0 ng/mL)

414 (84%)

Abnormal PSA velocity

39 (8%)

Digital rectal exam

37 (8%)

Baseline PSA
< 4 ng/mL*
4 ng/mL - 10 ng/mL

37 (8%)
318 (65%)

> 10 ng/mL

98 (20%)

Not collected (Screen = DRE)

37 (8%)

Cancer diagnosis
No cancer or resolved with repeat PSA

244 (50%)

Cancer

170 (35%)

Unresolved

76 (16%)

Abbreviations: PSA, prostate specific antigen; ng/mL, Nanogram per milliliter;
DRE, Digital rectal exam.
*Values may not sum to all subjects who enrolled on abnormal PSA velocity
due to rounded PSA value.

time to diagnostic resolution and time to treatment initiation. Since patients were followed for one year, events
that occurred within 365 days from abnormal screen for
Time 1 or 365 days from diagnosis for Time 2 will be
considered events in the statistical analysis. For unadjusted analyses, we will calculate Kaplan-Meier curves,
use them to determine median times within groups, and
compare curves between groups using the log-rank test.
For adjusted analyses, we will use proportional hazards
regression. Covariates will include age and race for Time
1, and age, race, and Gleason score for Time 2. In
addition to using a p-value testing whether the hazard
ratio (HR) was 1.0 or not, we will use adjusted hazard
ratios (HR) and 95% confidence intervals.
Exploratory analyses

Primary outcomes

To evaluate our primary outcome measures, we will perform unadjusted and adjusted time-to-event analyses for

For secondary outcomes, exploratory analysis will be
conducted to evaluate patient characteristics that may be
associated with delay of or non-compliance with
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diagnostic resolution in the intervention arm. Descriptive statistics will be obtained for each variable. Demographic characteristics and baseline scores on each
survey instrument will be uniformly entered into one
model for analysis, and multivariate linear regression
models will be used to evaluate the relationship between
potential predictor variables (literacy, stress, social support, distrust, etc.) and the dependent variable: days between abnormal prostate screening test and diagnostic
resolution. In addition to multivariate linear regression
models, multiple logistic regression models will be used
to explore the relationship between demographic or psychosocial variables and overall adherence to screening
follow-up, patient satisfaction, and navigation intensity.

Discussion
Patient navigation programs have been primarily undertaken within the breast cancer setting [5,37]. Because
prostate cancer differs in disease progression and quality
of life implications, however, the investigation of the efficacy of patient navigation within the prostate cancer
continuum is warranted. Weinrich et al. previously
reported that the use of a prostate cancer education program combined with a navigator resulted in increased
prostate cancer screening rates among African American
men [38]. Yet, to date, no studies have been published
on the effect of patient navigation on compliance with
prostate cancer diagnosis or treatment among men with
an abnormal prostate screening test. Our study is the
first to evaluate these outcomes.
Given equivocal evidence presented in the PLCO and
ERSPC studies on the efficacy of prostate cancer screening in reducing mortality [39,40], attention needs to be
directed at intervention entry points (screening, cancer
diagnosis, treatment), particularly for prostate patient
navigation interventions. It is well settled that an elevated PSA can represent several medical conditions beyond prostate cancer, including prostatitis and benign
prostatic hypertrophy. PSA can also be artificially and
transiently elevated by recent digital rectal examination,
prostate needle biopsy, and recent sexual activity. Therefore, the limitations of an abnormal PSA test alone must
be taken into consideration when implementing a navigation intervention. Our study adequately addressed this
concern, as it focused on men whose prostate cancer
screening results, history, and clinical presentation to
the urologist reflected a high probability of prostate cancer, thus resulting in a referral for biopsy.
In addition, our study was uniquely implemented at a
VA hospital, an equal-access setting with a range of preventive and treatment services. Prior to implementation
of the PNRP, most studies reporting on efficacy of navigation on screening, diagnosis, or treatment had been
conducted in the community clinic setting [5,37].
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Despite reduced financial barriers to entry, however, a
study examining over thirteen thousand veterans with
an abnormal prostate cancer screening test result found
that one-third received incomplete follow-up [41]. Our
study site involved rotating resident physicians from two
large academic research hospitals, at times introducing
disconnect in provider-patient relationships, which may
impact resolution rate [42,43]. Our patient navigators
filled this gap by building rapport and trust through the
tenure of the patient’s cancer care continuum to ensure
that abnormal screens reached resolution.
While the methods we outlined in this study were
compatible with our clinic site, they may not be
generalizable across non-VA facilities, facilities with multiple genders, different geographic regions, and nonurban settings. Given centralized care at the VA, we
chose a hospital-based framework, whereas other PNRP
programs extended into patients’ homes and communities to best meet the needs of their targeted populations
[44]. Additionally, the average age of men in our study
was 65, mandating clinical considerations more specific
to the elderly and the weighing of risks and benefits of
the more aggressive therapies usually reserved for and
selected by younger patients, particularly within the VA
[45]. While caution relative to overtreatment resonates
across all age groups in the literature, some studies raise
the issue of under treatment of cancer among the elderly
and support risk-stratified approaches to prostate cancer
care management [46,47]. Against this backdrop, a large
component of our patient navigation intervention focused on facilitating patient education and connecting
patients with resources to guide them through the treatment decision-making process.
Throughout the implementation of the intervention,
we learned many valuable lessons that may benefit emerging navigation programs. First, as previously described,
in response to repetition between the roles of our initial
nurse practitioner navigator and clinic-based nurses, we
adapted our model to include a social worker and lay
health navigator who worked closely with the VA nurses
to facilitate clinical needs. Programs planning navigation
team composition should consider utilizing existing providers with the requisite knowledge. This approach supports a smooth clinical research transition and facilitates
timely study initiation. Second, our project was originally
designed to prospectively enroll navigated and control
participants at two demographically similar VA outpatient clinics. Due to a hospital merger prior to accrual,
we adapted our design to include a concurrent recordsbased control group drawn from the same VA clinic as
the navigated patients. Future navigation studies should
similarly be prepared to adapt quickly to unanticipated
clinic site changes. Finally, since our navigators lacked
access to the VA appointment scheduling system, they
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focused on patient adherence to scheduled visits to prevent delayed follow-up. Thus, intervention approaches
that similarly comprise proactive measures—envisioning
and actuating issues that could introduce delay—rather
than reactively resolving patient-identified barriers can
be invaluable in reaching targeted navigation goals.

Conclusion
Racial/ethnic disparities in prostate cancer outcomes
have been well documented, and patient navigation
represents one strategy that has proven effective in improving timeliness of diagnostic resolution in community health centers and breast cancer settings. The goal
of our patient navigation study was not to alter prostate
cancer screening practices at the VA hospital; rather, we
sought to work within the existing systems framework to
provide a more patient-centered and disease-specific approach to ensuring patient adherence with prostate cancer
care. We focused on navigating low-income individuals
within the VA with an abnormal finding consistent with
prostate cancer, which arguably might not address the
potential navigational needs of similarly situated men
outside the VA system. Further research that utilizes novel
methodologies and is directed at examining navigation
interventions for men with prostate cancer who lack VA
support is needed.
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